Memory of Insulin Pumps and Their Record as a Source of Information About Insulin Therapy in Children and Adolescents with Type 1 Diabetes
- 1 April 2005
- journal article
- case report
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 7 (2) , 308-314
- https://doi.org/10.1089/dia.2005.7.308
Abstract
Background: This study was designed to provide information regarding basal and bolus insulin dosage in children and adolescents using continuous subcutaneous insulin infusion (CSII) and to evaluate the safety and efficacy of the CSII method in youths. Patients and Methods: Data from 100 patients (1.6–18 years old) were collected during scheduled visits in an outpatient clinic. The mean duration of diabetes was 4.57 years (range 0.6–16 years), and mean duration of CSII therapy was 1.75 years (range 0.5–3.0 years). Each child had his or her insulin doses reviewed using the Medtronic MiniMed (Northridge, CA) Pumps&Meters software program. At each visit glycosylated hemoglobin (HbA1c) values and growth parameters (weight and height) were assessed, and episodes of severe hypoglycemia and ketoacidosis were recorded. Results: The mean HbA1c value in our study group was 7.63 ± 0.09% (range, 5.15–12.5%). Statistically significant better metabolic control was found in children under 10 years of age, in children with lower body mass index (r = 0.33), in patients with a lower contribution of basal insulin to the total daily dose (r = 0.35; P < 0.05), and in boys. Ten percent of participants skipped mealtime boluses, which correlated with their glycemic control; in those children HbA1c was 8.67 ± 0.57% (r = 0.34; P < 0.05). The mean total daily insulin was 0.79 ± 0.02 U/kg/day (range, 0.3–2.0 U/kg/day). Basal insulin constituted on average 35.6 ± 1.1% (5–70%) of the daily insulin dose. We found a statistically significant higher contribution of basal insulin dose in patients who missed mealtime boluses (r = 0.42; P < 0.05) and a significantly lower contribution in pre-pubertal children and in boys (P < 0.05). Around 7% of patients made mistakes in programming the basal insulin. Conclusions: CSII may be safely and efficiently used in children with type 1 diabetes in different age groups. This method of treatment requires regular visits to an outpatient clinic, proper education, and frequent revisions of the pump's memory.Keywords
This publication has 12 references indexed in Scilit:
- Missed Insulin Meal Boluses and Elevated Hemoglobin A1c Levels in Children Receiving Insulin Pump TherapyPediatrics, 2004
- Insulin Pump TherapyDiabetes Care, 2003
- The Business of Insulin Pumps in Diabetes Care: Clinical and Economic ConsiderationsClinical Diabetes, 2002
- Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.Diabetes Care, 1999
- Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000Diabetes/Metabolism Research and Reviews, 1999
- Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I DiabetesDiabetes Care, 1996
- Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitusDiabetes Research and Clinical Practice, 1995
- Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications TrialThe Journal of Pediatrics, 1994
- Cortisol production rate in childhood and adolescenceThe Journal of Pediatrics, 1990
- Impaired Insulin Action in PubertyNew England Journal of Medicine, 1986